References
- Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171: 2186–90
- Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995; 153: 934–41
- Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stöckle M, Sternberg C. Guidelines on bladder cancer. Eur Urol 2002; 41: 105–12
- Dawkins GP, Miller RA. Sorbitol–mannitol solution for urological electrosurgical resection – a safer fluid than glycine 1.5%. Eur Urol 1999; 36: 99–102
- Witjes JA, Melissen DO, Kiemeney LA. Current practice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey. Eur Urol 2006; 49: 478–84
- Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T, et al. Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002; 94: 2363–8
- Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006; 175: 2004–10
- Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149: 749–52
- Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999; 161: 1120–3